Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 5,842

Document Document Title
WO/2018/011747A1
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...  
WO/2017/219083A1
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...  
WO/2017/202376A1
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.  
WO/2017/167315A1
Provided are an anthracenyl organic dye and a preparation method therefor. The organic dye has the structure shown in formula (I) or formula (II), wherein Ra, Rb and R2-1 – R2-4 are defined in the present document. The organic dye is p...  
WO/2017/165256A1
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...  
WO/2017/160922A1
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.  
WO/2017/129121A1
The present invention relates to 1,2,3,-thiadiazole oxime ether strobilurin derivatives having a general chemical structure as shown in IV. Provided in the present invention are thiadiazole oxime ether strobilurin derivatives, a preparat...  
WO/2017/122209A2
Disclosed herein are compounds capable of inhibiting dimerization of NF-κB, for example, p65-p65 homodimerization and/or p50-p65 heterodimerization, the compounds being represented by formula I: X-L2-L1-L'2-Y Formula I wherein X, Y, L1,...  
WO/2017/112947A1
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders or other diseases and disorders.  
WO/2017/106505A1
Provided herein are compounds that can bind GAS5 long non-coding RNA, compositions thereof, and uses thereof.  
WO/2017/106226A1
Disclosed are compounds of Formula A, or a salt thereof: Formula (A) wherein R1, R2, and E are defined herein, which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also describe...  
WO/2017/098421A1
The invention is directed to substituted benzothiadiazine derivatives. Specifically, the invention is directed to compounds according to Formula (I):wherein R, R1, R2, R3, R4 and R5 are as defined herein. The compounds of the invention a...  
WO/2017/079678A1
The invention relates to a novel variable hydrate crystalline form of 1-(5-(4-chloro-3,5-dimethoxyphenyl)furan-2-yl)-2-ethoxy-2-(4 -(5-methyl-1,3,4-thiadiazol-2-yl)phenyl)ethanone, methods for the preparation thereof, pharmaceutical comp...  
WO/2017/059303A1
Provided herein are vinylogous thioester compounds and methods for using the compounds.  
WO/2017/051353A1
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...  
WO/2017/051354A1
Provided are compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of HIV; including the prevention of the p...  
WO/2017/049158A1
The present invention provides a compound having the structure of the instant invention or a pharmaceutically acceptable salt or ester thereof, methods of preparing the same, and methods of treating a subject with compounds of the instan...  
WO/2017/042188A1
The present invention relates to a highly convergent method for the synthesis and purification of ceftolozane and intermediates starting from 7-aminocephaiosporanic acid (7- ACA).  
WO/2017/030122A1
This lubricant comprises an ionic liquid that includes a conjugate base and a conjugate acid, the conjugate acid having a group that includes a linear hydrocarbon group with at least six carbon atoms, pKa in acetonitrile of the acid whic...  
WO/2017/012965A1
The invention relates to substituted heteroaryl carboxylic acid hydrazides of general formula (I) or salts thereof, wherein the groups of formula (I) have the definitions stated in the description, for increasing the stress tolerance in ...  
WO/2017/009651A1
The invention provides a compound which is a diazine of formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt thereof, for use as an antifungal agent: (I) wherein X, N', C', A and E are as defined herein. The invention...  
WO/2017/005717A1
The present application relates to thiadiazole compounds, compositions containing such compounds, their use for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for the preparation ...  
WO/2017/004609A1
The invention is directed to compounds of the formula: wherein each of the variables are defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance treating an autoimmune disease.  
WO/2017/002100A1
New heterocyclic trifluoroalkenyl compounds having formula (I): Het-S(O) n-(CH 2) m-CF=CF 2 agronomic compositions containing them and their use for the control of nematodes in agricultural crops, are described.  
WO/2016/210414A1
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...  
WO/2016/193459A1
The present invention relates to compounds according to Formula I: or a pharmaceutically acceptable salt thereof. The compounds can be used as inhibitors of RORy and are useful for the treatment of RORy mediated diseases such as autoimmu...  
WO/2016/189877A1
The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the...  
WO/2016/172425A1
Compounds of Formulas I-VI, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth. Formula I is exemplified below: Formula (i)  
WO/2016/168059A1
This disclosure relates to the field of moiecuies having pesticida i utility against pests in Phyla Arthropoda, Moliusca, and hJematoda, processes to produce such moiecuies, intermediates used In such processes, pesticidai compositions c...  
WO/2016/168058A1
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...  
WO/2016/142852A1
The present invention relates to 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD-1) signaling pathway and/or for treatment of disorders by inhibiting an immunosuppressive...  
WO/2016/130043A1
The subject matter of this invention is novel inhibitors of hepatitis B virus replication, which are 1,1-dioxo-1,4-dihydro-2H-benzo[1,2,4]thiadiazine-3-ones of general formula 1, pharmaceutically acceptable salts and/or hydrates there...  
WO/2016/128541A1
The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.  
WO/2016/114345A1
The present invention addresses the problem of providing a polymerizable compound and a polymerizable composition unlikely to cause a decrease in phase difference or discoloration when a film-shaped polymer obtained by polymerization is ...  
WO/2016/108249A1
Disclosed herein are novel five membered heterocyclic compounds of Formula (I) wherein, X is S or SO2; n is 0, 1; m is1 or 2; Y is N, O or S; R2 independently represents H or alkyl or halo selected from -CI, -F; or -CF3, or -OH or-NH2 or...  
WO/2016/108282A1
 A compound represented by general formula (III), and the use of a tautomer or stereoisomer of said compound, or a pharmacologically acceptable salt or solvate thereof, as a treatment for gout or hyperuricemia. (III) (In the formula, R...  
WO/2016/097626A1
The invention relates to novel compounds, to the synthesis method thereof and to the use of same in medicine and in cosmetics. The invention relates to novel compounds, ligands that modulate RAR receptors.  
WO/2016/100897A1
Thiadiazolyl-oximinoacetic acid derivatives have been synthesized, which are useful in the manufacture of cephalosporin antibiotic compounds. Compound (1 ) (TATD) is commercially available (CAS No. 76028-96-1 ). It has now been discovere...  
WO/2016/087257A1
Compounds of formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides and can be prepared in...  
WO/2016/083303A1
The present invention provides process for the preparation of polymers comprising at least unit of formula (1), which process comprises the step of (v) treating a compound of formula (5), wherein Y2 is I, Br, CI or O-S(O)2CF3, with an S-...  
WO/2016/077629A1
Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers, optionally in combination with growth hormone, to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological...  
WO/2016/059093A1
The present invention relates to sulfonylurea analogous compounds comprising a sulfonylurea moiety and a photoresponsive moiety. The present invention further relates to methods for generating the sulfonylurea analogous compounds of the ...  
WO/2016/052439A1
 A method for producing 5-amino-3 substituted-1,2,4-thiadiazole, the method having a step for obtaining a compound represented by formula (II) by sequentially adding a brominating agent and a base to a mixture that includes an alcohol,...  
WO/2016/053767A1
The present invention provides four crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliorating, and/or delaying the onset of an Aβ pa...  
WO/2016/042435A1
The present invention relates to new thiadiazoles having general formula (I) and their use as herbicides.  
WO/2016/037595A1
The invention relates to substituted l,2,3-thiadiazol-5yl-urea derivatives, their use as anti- senescence and anti-stress factors of plant cells, organs and the whole plant, and preparations containing these derivatives.  
WO/2016/030443A1
Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2016/025364A1
The present invention provides a novel synthesis of verubecestat, and two novel crystalline forms of verubecestat, as well as pharmaceutically acceptable compositions thereof, each of which may be useful in treating, preventing, ameliora...  
WO/2016/025632A1
The present invention relates to new semiconducting compounds having at least one optionally substituted benzo[d][1,2,3]thiadiazole moiety. The compounds disclosed herein can exhibit high carrier mobility and/or efficient light absorptio...  
WO/2016/015593A1
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or ...  

Matches 1 - 50 out of 5,842